Why this fund manager is 'very happy' to own this ASX 200 share

The ASX 200 stock has come under some selling pressure in 2023, but this fundie sees better days ahead.

| More on:
A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

S&P/ASX 200 Index share CSL Ltd (ASX: CSL) is historically a long-term outperformer. But the stock has struggled in 2023.

Shares in the biotechnology company are currently trading for $266.80 apiece, down 5.3% since the opening bell of 3 January. That compares to a 3% gain posted by the ASX 200.

Here's why the ASX 200 share has come under pressure. And why this fund manager is "very happy" to own the biotech company.

What's happening with the ASX 200 share?

As you can see in the chart above, the CSL share price really hit some turbulence on 14 June.

That came after the ASX 200 share announced a downgrade of its FY 2023 profit guidance. This was driven by higher than initially forecast foreign currency headwinds.

At the time, CSL revised its forecast for its full-year net profits after tax and amortisation (NPATA) to the range of US$2.9 billion to US$3 billion in constant currency.

That revision saw the ASX 200 share close the day down 6.9%.

CSL reported its audited results on 15 August. And NPATA came in right near the bottom end of that forecast, at US$2.86 billion.

Other highlights of the FY 2023 results included a 31% increase in revenue in constant currency to US$13.31 billion. And the full-year dividend increased 6% to US$2.36 per share.

Management also reaffirmed its FY 2024 guidance. They expect NPATA of in the range of US$2.9 billion to US$3 billion in constant currency. And FY 2024 revenue growth of 9% to 11%.

Which brings us to Patrick Hodgens, managing director Firetrail Investments.

CSL counts amongst the biggest holdings at Firetrail Investments' high conviction fund.

And Hodgens wasn't put off by the ASX 200 share's results.

According to The Australian Financial Review, Firetrail believes this is a case of CEO Paul McKenzie "looking to reset".

According to Hodgens:

We're very happy to be owning CSL over the medium term and, in fact, we bought quite a bit more on the back of that perceived weakness by the market. We think CSL has some really good earnings upside if you look out two to three years.

CSL share price snapshot

As mentioned above, the CSL share price has underperformed in 2023 and over the past 12 months.

The ASX 200 share has outperformed longer-term, up 27% in five years.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Healthcare Shares

Buy CSL shares for growing dividends and 'compelling long-term tailwinds'

CSL has increased both its interim and final dividend every year since 2021.

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

Resmed share price higher despite CEO hitting sell on 14,683 shares

ResMed's CEO just sold $4.8 million worth of his own company's shares.

Read more »

Scientist looking at a laptop thinking about the share price performance.
Healthcare Shares

Why this high-flying ASX 200 healthcare stock just crashed 11%

Neuren Pharmaceuticals just dropped its 1Q FY24 report on DAYBUE sales.

Read more »

medical asx share price represented by doctor giving thumbs up
Healthcare Shares

Bell Potter says this ASX biotech stock could rocket 80%

Investors with a high tolerance for risk may want to check out this stock.

Read more »

Happy, tablet or doctor in a laboratory with research results or positive feedback after medical data analysis. Smile, vaccine or healthcare worker reading or working on futuristic science innovation.
Healthcare Shares

This ASX 200 healthcare stock is rocketing 8% following a record month!

Investors are impressed with this update. Here's why.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

3 reasons CSL stock is a great long-term investment

CSL has been a high-performing stock. Is it a buy today? UBS has the answer.

Read more »

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

Down 10% since mid-March, are Medibank shares a buy or a sell?

Is this stock a healthy opportunity?

Read more »

Three Archer Materials scientists wearing white coats and blue gloves dance together in their lab after making a discovery
Healthcare Shares

Which ASX 200 healthcare share with AI upside just hit a new 52-week high?

And top broker Goldman Sachs says the share price can go even higher.

Read more »